NGEN NervGen posts narrow Q3 beat as clinical pipeline advances CEO reaffirms confidence in nerve repair therapy NAUT Nautilus Biotechnology quarterly results under review as market awaits full earnings disclosure and segment analysis Is Amtech ASYS stock fairly valued Dips 20260423 Arqit ARQQ Stock Key Catalysts Ahead Arqit posts 256 per share loss on 530B revenue ADACU Am Drive Acq outlines key mobility sector acquisition targets during its latest quarterly earnings update